Immatics Announces Full Year 2024 Financial Results and Business Update
Randomized-controlled Phase 3 trial, SUPRAME, to evaluate ACTengine® IMA203 TCR-T (PRAME) in advanced melanoma patients;…
Newsrooms
DECHEMA and Gulf Energy Information partner to launch leading US event for process technology
DECHEMA – organizers of the world’s leading trade show for the Process Industries ACHEMA – and Gulf Energy Information a…
Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME
Today, Company discloses first clinical data from the TCR Bispecific molecule, TCER® IMA402 targeting PRAME, in the Phas…
Immatics Announces Pricing of $150 Million Public Offering
Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and develop…
Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial
Company announces updated Phase 1b clinical data on ACTengine® IMA203 targeting PRAME in 28 heavily pretreated metas…
TME Pharma Announces Acceptance of the NCI’s Abstract on NOX-A12 in Glioblastoma ior Presentation at the SNO 2024 Annual Meeting
Presentation will feature the results of the work conducted by the National Cancer Institute on inhibition of CXCL12 Res…
Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development Update
TCER® IMA401 is a novel, next-generation, half-life extended bispecific T cell engager directed against an HLA-A*02-pres…
Immatics Announces Second Quarter 2024 Financial Results and Business Update
Clinical data from May 2024 on ACTengine® IMA203 targeting PRAME in 30 heavily pre-treated metastatic melanoma patients…
Immatics Appoints Alise Reicin to Board of Directors
Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the dis…
Immatics Announces First Quarter 2024 Financial Results and Business Update
Updated clinical data on ACTengine® IMA203 targeting PRAME in 30 heavily pre-treated metastatic melanoma patients at RP2…
